Trial abstract · §3
TRIUMPH-2 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Percentage change in body weight from baseline at the primary analysis timepoint in participants with type 2 diabetes | no result held by the Institute | Not rated |
| The Institute publishes no effect estimate for a trial whose report it does not hold. | ||
§3.2Harms as reported
Table 5. Adverse events for Retatrutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 35.0 | 13.0 | Phase 2 obesity trial (12 mg, 48 weeks) |
| Diarrhoea | 29.0 | 9.0 | Phase 2 obesity |
| Vomiting | 24.0 | 2.0 | Phase 2 obesity |
| Constipation | 20.0 | 9.0 | Phase 2 obesity |
| Increased heart rate | — | — | Dose-dependent rise of approximately 6–10 beats/min at higher doses, attenuating by week 24 |
| Discontinuation for adverse events | 16.0 | 4.0 | Phase 2 obesity (highest dose cohort) |
Compound Evidence Institute · CEI-TR-0039/3 · https://compoundevidence.com/trials/triumph-2/results/ · retrieved 30 July 2026